INV4
1年前
Adial Pharmaceuticals appoints new COO Tony Goodman
Published 21/03/2025
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a $4.7 million market cap company specializing in pharmaceutical preparations, has announced the appointment of Tony Goodman as its new Chief Operating Officer (COO), effective April 1, 2025. According to InvestingPro data, the company maintains a strong liquidity position with cash reserves exceeding debt levels. This executive move comes after Mr. Goodman’s interim role as COO since January 2024 under a Master Services Agreement with The Keswick Group, LLC.
The company, headquartered in Glen Allen, Virginia, disclosed the new employment agreement in a recent SEC filing. The agreement outlines a three-year term with an annual base salary of $300,000 for Mr. Goodman. Additionally, he is eligible for a discretionary bonus of up to 30% of his base salary, contingent upon achieving certain objectives set by the board of directors. This appointment comes as the company’s stock trades at $0.74, down nearly 58% over the past year.
The filing also detailed severance provisions, stating that Mr. Goodman would be entitled to six months’ severance pay if terminated without cause, and twelve months’ severance following a change of control at the company.
There are no reported family relationships between Mr. Goodman and any of the company’s directors or executive officers, nor are there any transactions involving Mr. Goodman that would require disclosure under SEC regulations.
This staffing update follows the termination of the Master Services Agreement and Statements of Work with The Keswick Group, LLC, which will be concluded as of the effective date of Mr. Goodman’s employment contract.
The information provided is based on a press release statement and the full text of the Goodman Employment Agreement, which was attached to the SEC filing. Investors should note that Adial’s next earnings report is scheduled for April 2, 2025. InvestingPro subscribers have access to additional insights, including 6 more key tips about the company’s financial health and growth prospects.
In other recent news, Adial Pharmaceuticals has reported several significant developments. The company received positive feedback from the FDA for its in vitro bridging strategy for its lead investigational drug, AD04, which is designed for treating Alcohol Use Disorder (AUD). This approval allows Adial to proceed with manufacturing clinical supplies for its Phase 3 clinical program. Additionally, Adial successfully completed a pharmacokinetic study for AD04, confirming its dose-proportional exposure and paving the way for further trials and potential FDA approval.
Adial Pharmaceuticals was also granted a new patent by the USPTO, which covers methods for identifying genetic markers that indicate a predisposition to substance use disorders and treating them with AD04. This patent is expected to enhance treatment efficacy by personalizing therapy according to a patient’s genetic profile. Furthermore, Rodman & Renshaw maintained a Buy rating for Adial, with a target price of $8.00, expressing confidence in the stock’s potential for significant returns.
The company’s efforts in advancing AD04 include plans to finalize its Phase 3 trial design and secure funding, either independently or through partnerships. Adial’s CEO, Cary Claiborne, highlighted these developments as crucial steps toward providing innovative treatments for addiction. These recent advancements reflect Adial’s ongoing commitment to addressing treatment gaps in addiction therapy.
https://uk.investing.com/news/sec-filings/adial-pharmaceuticals-appoints-new-coo-tony-goodman-93CH-3992097
============================
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
AD04
For Alcohol Use Disorder (AUD)
AUD is a disease effecting greater than 35 million people in the US alone. For about 20% of this group there is a specific genetic component which Adial has identified and developed a genetic biomarker test which indicates its lead compound AD04 should be highly effective in controlling cravings and heavy and binge drinking and supporting abstinence.
AD04
The Company’s lead compound AD04 (“AD04”) is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and was recently investigated in a Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which were identified using the Company’s proprietary companion diagnostic genetic test.
The resulting data indicate a statistically significant response in the reduction of heavy drinking days in a subgroup of patients. The subgroup consisted of patients who drank fewer than 10 drinks per drinking day and comprised about two-thirds of the patients enrolled into the study. Adial is in the process of engaging regulatory authorities to refine the future development of AD04.
Adial possesses a world-wide, exclusive license from the University of Virginia Patent Foundation to commercialize AD04, subject to FDA approval of the product, based upon three (3) separate patents and patent application families, with patents filed and issued in over 40 jurisdictions, including 3 issued patents in the U.S. AD04 has been used in several investigator-sponsored trials and we possess or have rights to use toxicology, pharmacokinetic and other preclinical and clinical data that support AD04 development.
AUD is a potentially multi-billion-dollar market with limited competition & unmet need (accounts for ~5.3% of deaths worldwide and ~5.1% of disease worldwide)
The Lancet reports that alcohol is the number one cause of death in the U.S. & globally among both men and women ages 15 to 49 years
Differentiated product
• Designed to reduce drinking levels (believed through reduction of craving)
• Potential to facilitate abstinence
• Limited side effects to date
https://www.adial.com/adial-pharmaceuticals-expands-intellectual-property-portfolio-with-new-u-s-patent-granted-for-genetic-based-treatment-of-alcohol-and-opioid-use-disorders/
https://www.adial.com
$ADIL
INV4
1年前
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
May 01, 2025
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.
This newly issued patent strengthens Adial’s intellectual property portfolio by covering the administration of AD04, the Company’s investigational drug, as a precision medicine approach for patients with specific genetic markers. The patent claims a method of treating addiction by administering a therapeutically effective amount of AD04 to patients with serotonin-related gene variations, including specific genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR in combination with variations in rs1150226, rs17614942, and rs1176713. The granted claims include specific genetic profiles associated with treatment efficacy and the corresponding dosing regimens. Specifically for AUD, the patent claims cover a method of treatment for a broad definition of alcohol related disorders including, but not limited to, disorders associated with alcohol use such as alcohol induced or associated anxiety, bi-polar, sexual dysfunction, sleep disorder, or gambling disorder as well as alcohol withdrawal.
“This patent represents yet another significant milestone for Adial Pharmaceuticals as we advance our mission to provide targeted treatments for individuals suffering from alcohol and opioid use disorders,” said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. “By identifying genetic markers associated with AD04 response, we are pioneering a precision medicine approach for AUD that has the potential to enhance treatment efficacy and improve patient outcomes. We remain committed to advancing AD04 through clinical development and regulatory pathways to address the urgent need for effective, personalized addiction treatments.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change to the millions of patients who are struggling with addiction.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
https://ih.advfn.com/stock-market/NASDAQ/adial-pharmaceuticals-ADIL/stock-news/95964989/adial-pharmaceuticals-expands-intellectual-propert
$ADIL
subslover
1年前
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use
GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.
This newly issued patent strengthens Adial’s intellectual property portfolio by covering the administration of AD04, the Company’s investigational drug, as a precision medicine approach for patients with specific genetic markers. The patent claims a method of treating addiction by administering a therapeutically effective amount of AD04 to patients with serotonin-related gene variations, including specific genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR in combination with variations in rs1150226, rs17614942, and rs1176713. The granted claims include specific genetic profiles associated with treatment efficacy and the corresponding dosing regimens. Specifically for AUD, the patent claims cover a method of treatment for a broad definition of alcohol related disorders including, but not limited to, disorders associated with alcohol use such as alcohol induced or associated anxiety, bi-polar, sexual dysfunction, sleep disorder, or gambling disorder as well as alcohol withdrawal.
“This patent represents yet another significant milestone for Adial Pharmaceuticals as we advance our mission to provide targeted treatments for individuals suffering from alcohol and opioid use disorders,” said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. “By identifying genetic markers associated with AD04 response, we are pioneering a precision medicine approach for AUD that has the potential to enhance treatment efficacy and improve patient outcomes. We remain committed to advancing AD04 through clinical development and regulatory pathways to address the urgent need for effective, personalized addiction treatments.”
subslover
1年前
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use
GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.
This newly issued patent strengthens Adial’s intellectual property portfolio by covering the administration of AD04, the Company’s investigational drug, as a precision medicine approach for patients with specific genetic markers. The patent claims a method of treating addiction by administering a therapeutically effective amount of AD04 to patients with serotonin-related gene variations, including specific genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR in combination with variations in rs1150226, rs17614942, and rs1176713. The granted claims include specific genetic profiles associated with treatment efficacy and the corresponding dosing regimens. Specifically for AUD, the patent claims cover a method of treatment for a broad definition of alcohol related disorders including, but not limited to, disorders associated with alcohol use such as alcohol induced or associated anxiety, bi-polar, sexual dysfunction, sleep disorder, or gambling disorder as well as alcohol withdrawal.
“This patent represents yet another significant milestone for Adial Pharmaceuticals as we advance our mission to provide targeted treatments for individuals suffering from alcohol and opioid use disorders,” said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. “By identifying genetic markers associated with AD04 response, we are pioneering a precision medicine approach for AUD that has the potential to enhance treatment efficacy and improve patient outcomes. We remain committed to advancing AD04 through clinical development and regulatory pathways to address the urgent need for effective, personalized addiction treatments.”
tw0122
2年前
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Source: GlobeNewswire Inc.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day), following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024.
Cary Claiborne, President and Chief Executive Officer of Adial commented, “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.”
The pharmacokinetics study was initiated in June 2024 and is expected to be completed during the fourth quarter of 2024. The single-center open-label relative bioavailability and dose proportionality study will enroll up to 30 healthy adult volunteers and compare the pharmacokinetic profile of AD04 when administered as an oral dose of 0.33 mg with or without food against a reference standard product. This study will provide valuable information on the pharmacokinetic properties of AD04.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
3週前
Zardiw
11月前
Chrion Capital
11月前
GhosTraderX
11月前
LowFloatLopes
1年前
FROZENFLAME
2年前
Monksdream
2年前
メールアドレスで登録
